Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Fitch: Pfizer Deal Highlights U.S. Pharma Trend for Targeted M&A

By Business Wire | August 24, 2016

Pfizer’s proposed acquisition of Medivation highlights the trend of large innovative U.S. pharmaceutical firms continuing to pursue targeted acquisitions rather than large transformative ones, according to Fitch Ratings.

Consolidation continues as big pharmaceutical firms search for scale and efficiencies. However, as the number of new drugs in the pipeline increases, and manufacturers face manageable patent expiry risks, large acquisitions will become less necessary. We expect larger manufacturers to seek out individual therapeutics and smaller biotech companies through targeted acquisitions and partnerships designed to strengthen innovative drug portfolios.

Pfizer’s deal announced this week is a good example. Medivation sells a prostate-cancer drug with significant growth potential in the oncology space and has two pipeline products. The all-cash deal for approximately $14 billion will be marginally positive for Pfizer’s leverage as the company will fund the acquisition with balance sheet cash while acquiring EBITDA from a product that is already on the market and growing. Notably, acquisitions and share repurchases during the past two years have strained leverage. However, the acquisition will be modestly negative for liquidity, which is generally solid given Pfizer’s strong FCF generation and ample access the credit markets.

Whether Pfizer will retain, spin off or sell its Global Established Pharmaceuticals business remains unclear. The company has said it will assess the merits of a separation by year-end 2016. We would view a divestiture as strategically positive for Pfizer, as it would narrow the company’s focus on its higher margin, innovative portfolio. However, the business model would be more reliant on its innovative drug discovery efforts, and it remains unclear whether the company would take a more conservative capital structure.

Pfizer’s acquisition of Anacor in June is another example of a recent targeted acquisition. Anacor’s eczema treatment crisaborole will be an important near-term asset for the company. Other transactions include Bristol-Myers Squibb’s acquisition of Padlock Therapeutics, which could expand its presence in the treatment of rheumatoid arthritis. In its acquisition of Glycostasis, Inc., Eli Lilly looks to develop a form of insulin that self-releases when a diabetic patient’s blood-sugar level is too high.

The above article originally appeared as a post on the Fitch Wire credit market commentary page. The original article can be accessed at www.fitchratings.com. All opinions expressed are those of Fitch Ratings.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50